You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – California-based drug company Aadi Bioscience and EOC Pharma, a firm based in China specializing in cancer therapies, have signed an exclusive licensing deal to develop and commercialize Aadi's mTOR inhibitor ABI-009 in Greater China.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.